Tesamorelin
- Generic Name
- Tesamorelin
- Brand Names
- Egrifta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 218949-48-5
- Unique Ingredient Identifier
- MQG94M5EEO
- Background
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretr...
- Indication
Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
- Associated Conditions
- Lipodystrophies
- Associated Therapies
- -
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
- Conditions
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06554717
- Locations
- 🇺🇸
University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
- Conditions
- Interventions
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT03375788
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Body Composition and Adipose Tissue in HIV
- Conditions
- Interventions
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 24
- Registration Number
- NCT03226821
- Locations
- 🇺🇸
Neuroendocrine Unit and Pituitary Center, Columbia University, New York, New York, United States
Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia
- Conditions
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- National Institute of Nursing Research (NINR)
- Registration Number
- NCT02931474
Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 73
- Registration Number
- NCT02572323
- Locations
- 🇺🇸
Keck School of Medicine of the University of Southern California, Los Angeles, California, United States
🇺🇸PalmTree, Palm Springs, California, United States
🇺🇸HIV Neurobehavioral Research Program (HNRP), San Diego, California, United States
Tesamorelin Effects on Liver Fat and Histology in HIV
- Conditions
- Interventions
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT02196831
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸National Institutes of Health, Bethesda, Maryland, United States
Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Theratechnologies
- Target Recruit Count
- 18
- Registration Number
- NCT02012556
- Locations
- 🇨🇦
Anapharm Montreal, Montreal, Quebec, Canada
Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01632592
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®
- Conditions
- Interventions
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Theratechnologies
- Target Recruit Count
- 129
- Registration Number
- NCT01591902
- Locations
- 🇺🇸
Capital Medical Associates, PC, Washington, District of Columbia, United States
🇺🇸Gary J. Richmond, M.D., PA, Fort Lauderdale, Florida, United States
🇺🇸5P21 Rand Schrader Clinic, Los Angeles, California, United States
Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting
- Conditions
- Interventions
- First Posted Date
- 2011-07-07
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Theratechnologies
- Target Recruit Count
- 3
- Registration Number
- NCT01388920
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.